NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.85 CHF | -0.18% |
|
-1.49% | -0.02% |
| Apr. 17 | Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years | MT |
| Apr. 17 | Novartis: positive efficacy data in MS | CF |
| Sales 2024 * | 48.13B 43.74B | Sales 2025 * | 49.85B 45.31B | Capitalization | 204B 185B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.65B 9.68B | Net income 2025 * | 11.58B 10.53B | EV / Sales 2024 * | 4.49 x |
| Net Debt 2024 * | 12.16B 11.05B | Net Debt 2025 * | 10.8B 9.81B | EV / Sales 2025 * | 4.3 x |
| P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
16.2
x | Employees | 76,057 |
| Yield 2024 * |
3.92% | Yield 2025 * |
4.05% | Free-Float | 81.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More press releases
| 1 day | -0.18% | ||
| 1 week | -1.49% | ||
| Current month | -2.88% | ||
| 1 month | -0.92% | ||
| 3 months | -9.40% | ||
| 6 months | -2.90% | ||
| Current year | -0.02% |
1 week
84.34
86.73
1 month
84.3488.83
Current year
84.3494.52
1 year
83.0094.77
3 years
72.8494.77
5 years
65.0996.38
10 years
65.09103.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 04-12-31 | |
| Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
| Chairman | 68 | 12-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | - | |
| 5.57% | 18 M€ | +2.91% | - | |
| 4.12% | 88 M€ | +10.37% | - | |
| 3.79% | 2 M€ | -25.75% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 84.85 | -0.18% | 2,429,911 |
| 24-04-16 | 85 | -1.73% | 3,068,722 |
| 24-04-15 | 86.5 | +0.46% | 2,331,975 |
| 24-04-12 | 86.1 | +0.55% | 2,419,969 |
| 24-04-11 | 85.63 | -0.58% | 2,226,966 |
Delayed Quote Swiss Exchange, April 17, 2024 at 11:31 am EDT
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
93.02
USD
Average target price
106.9
USD
Spread / Average Target
+14.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.02% | 204B | |
| +28.79% | 676B | |
| +24.81% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +2.47% | 210B | |
| -9.98% | 194B | |
| -11.71% | 144B | |
| -8.32% | 142B |
- Stock Market
- Equities
- NOVN Stock
